NEUROPROTECTIVE ACTIVITY OF MINOCYCLINE IN CEREBRAL ISCHEMIA: SYSTEMATIC REVIEW

Abstract

Stroke is caused by interruption of cerebral blood flow and may be of ischemic genesis. The subtypes are determined according to the origin, being: atherosclerosis of large arteries, cardioembolism, occlusion of small arteries, of other determined origins and unknown origin. The pharmacological treatment is the Tissue Plasminogen Activator, of narrow therapeutic window. Minocycline can cross the blood-brain barrier, acting on neuronal loss, becoming a neuroprotective potential of high applicability and specificity, blocking cellular groups responsible for the inflammatory and degenerative process. The objective was carry on a systematic review. The used, with the descriptors: minociclina/neuroproteção and minocycline/neuroprotection, only sevem studies were selected, published between 2014 and 2018 available in full for free. Minocycline correlates with inhibition of NF-κB in neurons, antioxidant, has anti-apoptotic effect, improvement in tissue damage, functional recovery in animals, involvement with MCP1P1, and correlation
with factor factors CREB, pCREB, and BDNF. The ability of neuroprotection obtained through minocycline treatment in ischemic models is remarkable. This promising therapy is definitively proven.